Patient Portal

Gavin P. Dunn, MD, PhD

Assistant Professor, Neurological Surgery
Assistant Professor, Pathology and Immunology
Center for Human Immunology and Immunotherapy Programs

Specialty Areas

Brain Tumors
Neuro Oncology
Neurosurgery
Immunotherapy
Gamma Knife

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Brain tumors, including glioma, astrocytoma, oligodendroglioma, glioblastoma; ependymoma, meningioma, metastatic brain tumors; neuro-oncology; Chiari malformation; hydrocephalus, including endoscopic third ventriculostomy; trigeminal neuralgia

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures
  • Videos

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Neuroscience Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 362-3577
Fax: (314) 362-2107

Education

Education

Residency: Neurological Surgery, Massachusetts General Hospital, Boston 2013
A.B.: Princeton University, Princeton, New Jersey 1998
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 2006
PhD: Washington University School of Medicine, St. Louis, Missouri 2006

Publication & Research

Publication & Research

Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, Kim AH, Dunn GP, Robinson CG, Chicoine MR, Huang J, Abraham CD
Radiother Oncol. 2018 Jun 27; pii: S0167-8140(18)33314-0. doi: 10.1016/j.radonc.2018.06.017.

PMID:
    29960685
    [PubMed - as supplied by publisher]
Related citations


Focused Ultrasound-enabled Brain Tumor Liquid Biopsy.
Zhu L, Cheng G, Ye D, Nazeri A, Yue Y, Liu W, Wang X, Dunn GP, Petti AA, Leuthardt EC, Chen H
Sci Rep. 2018 Apr 26; 8(1)6553. doi: 10.1038/s41598-018-24516-7.

PMID:
    29700310
    [PubMed - in process]
Related citations


Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient.
Miller CA, Dahiya S, Li T, Fulton RS, Smyth MD, Dunn GP, Rubin JB, Mardis ER
Cold Spring Harb Mol Case Stud. 2018 Apr; 4(2)pii: a002444. doi: 10.1101/mcs.a002444.

PMID:
    29440180
    [PubMed - in process]
Related citations


T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, Elsamadicy AA, Cui X, Koyama S, Jackson C, Hansen LJ, Johanns TM, Sanchez-Perez L, Chandramohan V, Yu YA, Bigner DD, Giles A, Healy P, Dranoff G, Weinhold KJ, Dunn GP, Fecci PE
Clin Cancer Res. 2018 Feb 7; doi: 10.1158/1078-0432.CCR-17-1846.

PMID:
    29437767
    [PubMed - as supplied by publisher]
Related citations


Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma.
Zolkind P, Przybylski D, Marjanovic N, Nguyen L, Lin T, Johanns T, Alexandrov A, Zhou L, Allen CT, Miceli AP, Schreiber RD, Artyomov M, Dunn GP, Uppaluri R
Oncotarget. 2018 Jan 9; 9(3)4109-4119. doi: 10.18632/oncotarget.23751.

PMID:
    29423108
    [PubMed]
Related citations


Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress.
Gelman SJ, Naser F, Mahieu NG, McKenzie LD, Dunn GP, Chheda MG, Patti GJ
Cell Rep. 2018 Jan 9; 22(2)512-522. doi: 10.1016/j.celrep.2017.12.050.

PMID:
    29320744
    [PubMed - in process]
Related citations


Erratum: Genomic landscape of high-grade meningiomas.
Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, A Ducar M, Thorner AR, van Hummelen P, O Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R
NPJ Genom Med. 2017; 226. doi: 10.1038/s41525-017-0023-6.

PMID:
    29263836
    [PubMed - in process]
Related citations


Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma.
Mahlokozera T, Vellimana AK, Li T, Mao DD, Zohny ZS, Kim DH, Tran DD, Marcus DS, Fouke SJ, Campian JL, Dunn GP, Miller CA, Kim AH
Neuro Oncol. 2018 Mar 27; 20(4)472-483. doi: 10.1093/neuonc/nox232.

PMID:
    29244145
    [PubMed - in process]
Related citations


Management of intracranial melanomas in the era of precision medicine.
Young GJ, Bi WL, Wu WW, Johanns TM, Dunn GP, Dunn IF
Oncotarget. 2017 Oct 24; 8(51)89326-89347. doi: 10.18632/oncotarget.19223.

PMID:
    29179523
    [PubMed]
Related citations


Direct puncture Onyx embolization of a large calvarial metastasis with intracranial extension: Case report.
Zhou MH, Dunn GP, Osbun JW, Cross DT 3rd, Moran CJ, Dacey RG Jr, Kansagra AP
Interv Neuroradiol. 2018 Apr; 24(2)220-224. doi: 10.1177/1591019917740353.

PMID:
    29119877
    [PubMed - in process]
Related citations


Comprehensive Analysis of Hypermutation in Human Cancer.
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A
Cell. 2017 Nov 16; 171(5)1042-1056.e10. doi: 10.1016/j.cell.2017.09.048.

PMID:
    29056344
    [PubMed - indexed for MEDLINE]
Related citations


Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
Mei Y, Du Z, Hu C, Greenwald NF, Abedalthagafi M, Agar NYR, Dunn GP, Bi WL, Santagata S, Dunn IF
Cell Commun Signal. 2017 Sep 18; 15(1)34. doi: 10.1186/s12964-017-0189-7.

PMID:
    28923059
    [PubMed - indexed for MEDLINE]
Related citations


Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.
Johanns TM, Bowman-Kirigin JA, Liu C, Dunn GP
Neurosurgery. 2017 Sep 1; 64(CN_suppl_1)165-176. doi: 10.1093/neuros/nyx321.

PMID:
    28899059
    [PubMed - in process]
Related citations


Genomic landscape of high-grade meningiomas.
Bi WL, Greenwald NF, Abedalthagafi M, Wala J, Gibson WJ, Agarwalla PK, Horowitz P, Schumacher SE, Esaulova E, Mei Y, Chevalier A, Ducar M, Thorner AR, van Hummelen P, Stemmer-Rachamimov A, Artyomov M, Al-Mefty O, Dunn GP, Santagata S, Dunn IF, Beroukhim R
NPJ Genom Med. 2017; 2pii: 15. doi: 10.1038/s41525-017-0014-7.

PMID:
    28713588
    [PubMed]
Related citations


Free ammonia offers algal crop protection from predators in dairy wastewater and ammonium-rich media.
Thomas PK, Dunn GP, Passero M, Feris KP
Bioresour Technol. 2017 Nov; 243724-730. doi: 10.1016/j.biortech.2017.07.008.

PMID:
    28711800
    [PubMed - indexed for MEDLINE]
Related citations


Genomic profile of human meningioma cell lines.
Mei Y, Bi WL, Greenwald NF, Agar NY, Beroukhim R, Dunn GP, Dunn IF
PLoS One. 2017; 12(5)e0178322. doi: 10.1371/journal.pone.0178322.

PMID:
    28552950
    [PubMed - indexed for MEDLINE]
Related citations


Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.
Johanns TM, Dunn GP
Cancer J. 2017 Mar/Apr; 23(2)125-130. doi: 10.1097/PPO.0000000000000247.

PMID:
    28410300
    [PubMed - indexed for MEDLINE]
Related citations


Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.
Uppaluri R, Winkler AE, Lin T, Law JH, Haughey BH, Nussenbaum B, Paniello RC, Rich JT, Diaz JA, Michel LP, Wildes T, Dunn GP, Zolkind P, Kallogjeri D, Piccirillo JF, Dehdashti F, Siegel BA, Chernock RD, Lewis JS Jr, Adkins DR
Clin Cancer Res. 2017 May 1; 23(9)2186-2194. doi: 10.1158/1078-0432.CCR-16-1469.

PMID:
    28151720
    [PubMed - indexed for MEDLINE]
Related citations


Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.
Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, Uppaluri R, Ferguson C, Schmidt RE, Dahiya S, Ansstas G, Mardis ER, Dunn GP
Cancer Discov. 2016 Nov; 6(11)1230-1236.

PMID:
    27683556
    [PubMed - indexed for MEDLINE]
Related citations


Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach.
Johanns TM, Ward JP, Miller CA, Wilson C, Kobayashi DK, Bender D, Fu Y, Alexandrov A, Mardis ER, Artyomov MN, Schreiber RD, Dunn GP
Cancer Immunol Res. 2016 Dec; 4(12)1007-1015.

PMID:
    27799140
    [PubMed - indexed for MEDLINE]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: Immunovalent

Royalties:

Equity: Yes

Consulting/Advisory Board:

Speaker Fees:

Reporting Date: May 01, 2018

Videos

Videos

Areas of Research Interest

Interaction of developing tumors and the immune system;  cancer immunogenomics (intersection of cancer immunology and genomics);  immune system recognition of malignant glioma